ILIAD BIOTECHNOLOGIES
ILiAD Biotechnologies (ILiAD) is a clinical-stage biotechnology company focused on the prevention and treatment of disease caused by Bordetella Pertussis. ILiAD's lead candidate is BPZE1, a live-attenuated pertussis vaccine that has successfully completed a Phase 1 human clinical trial. ILiAD Biotechnologies is a registered Delaware company founded in 2012.
ILIAD BIOTECHNOLOGIES
Industry:
Biotechnology Clinical Trials Health Care Pharmaceutical
Founded:
2012-01-01
Address:
New York, New York, United States
Country:
United States
Website Url:
http://www.iliadbio.com
Total Employee:
11+
Status:
Active
Contact:
(917)913-8511
Email Addresses:
[email protected]
Total Funding:
64.99 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default Google Analytics Google Universal Analytics Apache Euro Google Apps For Business Google Maps YouTube
Similar Organizations
Aura Biosciences
Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor targeted pseudovirions.
Novavax
Novavax is a clinical-stage biotechnology company focused on the discovery and development of innovative vaccines.
Current Employees Featured
Founder
Investors List
Knott Partners
Knott Partners investment in Series D - ILiAD Biotechnologies
National Institute of Allergy and Infectious Diseases
National Institute of Allergy and Infectious Diseases investment in Grant - ILiAD Biotechnologies
Network-1
Network-1 investment in Venture Round - ILiAD Biotechnologies
JEMS Venture Capital
JEMS Venture Capital investment in Venture Round - ILiAD Biotechnologies
SDS Capital Partners
SDS Capital Partners investment in Venture Round - ILiAD Biotechnologies
Seedlings Life Science Ventures
Seedlings Life Science Ventures investment in Venture Round - ILiAD Biotechnologies
Official Site Inspections
http://www.iliadbio.com Semrush global rank: 5.76 M Semrush visits lastest month: 1.45 K
- Host name: 177.56.180.107.host.secureserver.net
- IP address: 107.180.56.177
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260
More informations about "ILiAD Biotechnologies"
ILiAD Biotechnologies - Crunchbase Company Profile …
Organization. ILiAD Biotechnologies . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. ILiAD is a clinical-stage biotechnology company focused on the prevention …See details»
ILiAD Biotechnologies, LLC | LinkedIn
ILiAD Biotechnologies, LLC Biotechnology Research Weston, Florida 913 followers ILiAD is advancing the next generation pertussis vaccine for the prevention of whooping cough.See details»
Fierce Biotech Names ILiAD Biotechnologies to its 2024 Fierce 15
WESTON, Fla., August 05, 2024--ILiAD Biotechnologies, LLC (ILiAD), a biotech company developing the most advanced next generation pertussis vaccine (BPZE1), announced today …See details»
ILiAD Biotechnologies - Overview, News & Similar companies
Oct 18, 2023 ILiAD Biotechnologies Announces Presentation at the 2023 World Vaccine Congress in Barcelona WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC …See details»
ILiAD Biotechnologies, LLC - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for ILiAD Biotechnologies, LLC of New York, NY. Get the latest business insights from Dun & Bradstreet.See details»
ILiAD Biotechnologies LLC - Drug pipelines, Patents, Clinical
Contacts Ken Solovay COO ILiAD Biotechnologies, LLC [email protected] 800.603.3525. ... About Emmes Group Emmes Group is a privately held contract research organization (CRO), …See details»
ILiAD Biotechnologies - Executive Board
ILiAD Biotechnologies is a clinical stage biotechnology company dedicated to the prevention and treatment of diseases caused by Bordetella Pertussis. Our lead candidate, BPZE1, represents the most advanced next generation pertussis …See details»
ILiAD Biotechnologies
BioLyo Technologies, BV is a wholly-owned ILiAD subsidiary based in Ghent, Belgium. The contract development manufacturing organization (CDMO), led by Marcel Thalen, PhD, …See details»
ILiAD Biotechnologies - PitchBook
Information on valuation, funding, cap tables, investors, and executives for ILiAD Biotechnologies. Use the PitchBook Platform to explore the full profile.See details»
Emmes partners with ILiAD Biotechnologies to Conduct Phase III …
Jun 24, 2024 Emmes Group is a privately held contract research organization (CRO), wholly owned by New Mountain Capital ... ILiAD Biotechnologies, LLC Email: [email protected] …See details»
ILiAD Biotechnologies Announces $42.8M Financing Round to …
Sep 6, 2022 Ken Solovay COO ILiAD Biotechnologies, LLC [email protected] 800.603.3525 Contacts. Ken Solovay COO ILiAD Biotechnologies, LLC [email protected] 800.603.3525 Site …See details»
ILiAD Biotechnologies Announces Planned Collaboration with …
Jun 24, 2024 ILiAD Biotechnologies, LLC Email: [email protected] Phone: (800) 603-3525 Emmes Group Dana Roche Director, Marketing & Communications [email protected] +1 …See details»
ILiAD Biotechnologies Announces Presentation at the World …
Apr 5, 2023 Press Contact: Ken Solovay COO ILiAD Biotechnologies, LLC [email protected] 800.603.3525 Contacts. Press Contact: Ken Solovay COO ILiAD Biotechnologies, LLC …See details»
ILiAD Biotechnologies
During Ms. Fix’s career, she has successfully conducted numerous global regulatory meetings, and has been responsible for multiple INDs, BLAs, NDAs, and post-marketing programs, has …See details»
ILiAD Biotechnologies BPZE1 Pertussis Vaccine Reaches Full …
Oct 8, 2019 WESTON, Fla.--(BUSINESS WIRE)--Oct 8, 2019-- ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most advanced next …See details»
ILiAD Biotechnologies Reports Positive Topline Interim Results …
WESTON, Fla., May 28, 2024--ILiAD Biotechnologies, LLC (ILiAD) reported today that BPZE1, the most advanced next generation pertussis vaccine, demonstrated positive topline interim …See details»
ILiAD Biotechnologies Receives NIH Grant to Develop Novel …
Apr 26, 2022 Ken Solovay ILiAD Biotechnologies 800.603.3525 [email protected]. Contacts. Ken Solovay ILiAD Biotechnologies 800.603.3525 [email protected]. Site Navigation. Home. …See details»
ILiAD Biotechnologies Announces Presentation of Positive
Sep 24, 2020 For further information, please visit www.iliadbio.com or follow us on Twitter. Contacts Ken Solovay ILiAD Biotechnologies, LLC 954.336.0777 [email protected]. Media …See details»
ILiAD Biotechnologies BPZE1 Pertussis Vaccine Reaches Full …
Oct 8, 2019 PPD is a leading global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services. ... LLC …See details»